Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

for the CA184-043, Investigators

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

In this preplanned long-term analysis, overall survival favored ipilimumab plus radiotherapy versus placebo plus radiotherapy for patients with postdocetaxel metastatic castrate-resistant prostate cancer. Beyond approximately 2 yr of follow-up, long-term survivors were two to three times more prevalent in the ipilimumab arm.

Original languageEnglish (US)
JournalEuropean urology
DOIs
StateAccepted/In press - 2020

Keywords

  • Immunotherapy
  • Ipilimumab
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors'. Together they form a unique fingerprint.

Cite this